Artesunate plus sulfamethoxypyrazine/pyrimethamine for the treatment of cutaneous leishmaniasis: a double-blind, placebo-controlled clinical trial
Authors:
- Ishag AdamIAIshag Adam
- 31 October 2009
- journal article
- other
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 34 (4) , 380-381
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The antischistosomal efficacies of artesunate–sulfamethoxypyrazine–pyrimethamine and artemether–lumefantrine administered as treatment for uncomplicated,Plasmodium falciparummalariaPathogens and Global Health, 2008
- Artemisinins and synthetic trioxolanes in the treatment of helminth infectionsCurrent Opinion in Infectious Diseases, 2007
- Advances in leishmaniasisThe Lancet, 2005
- Miltefosine to treat leishmaniasisExpert Opinion on Pharmacotherapy, 2005
- Structure−Activity Relationships of the Antimalarial Agent Artemisinin. 8. Design, Synthesis, and CoMFA Studies toward the Development of Artemisinin-Based Drugs against Leishmaniasis and MalariaJournal of Medicinal Chemistry, 2003
- Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasisParasitology, 1993